Regenxbio (RGNX) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • Thursday
REGENXBIO to Host Conference Call on November 5 to Discuss Third Quarter 2026 Financial Results and Operational HighlightsPRNewsWire • Thursday
REGENXBIO Inc. (RGNX) Discusses Clinical Program Progress and Commercial Outlook in Wet AMD and Rare Diseases TranscriptSeeking Alpha • 10/21/26
REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20PRNewsWire • 10/12/26
REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific MeetingPRNewsWire • 09/24/26
REGENXBIO Inc. (RGNX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/16/26
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of REGENXBIO Inc. (RGNX)Business Wire • 08/25/26
RGNX Stock Slumps 25% on FDA Clinical Hold for RGX-121 Gene TherapyZacks Investment Research • 08/25/26
RGNX Investor Notice: Johnson Fistel Investigates REGENXBIO Inc. Following Clinical HoldGlobeNewsWire • 08/24/26
REGENXBIO Reports Second Quarter 2026 Financial Results and Operational HighlightsPRNewsWire • 08/06/26
REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational HighlightsPRNewsWire • 08/03/26